Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8540)
All Articles published online
|
Publishing Process of This Article
|
Jun 7, 2014 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Sugimoto M, Furuta T. Efficacy of tailored |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i21/6400.htm |
| Number | Citing Articles |
| 1 |
Nihal El Rouby, John J. Lima, Julie A. Johnson. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opinion on Drug Metabolism & Toxicology 2018; 14(4): 447 doi: 10.1080/17425255.2018.1461835
|
| 2 |
Michiel C. Mommersteeg, Stella A. V. Nieuwenburg, Leonieke M. M. Wolters, Buddy H. C. M. Roovers, Hanneke A. J. van Vuuren, Auke P. Verhaar, Marco J. Bruno, Ernst J. Kuipers, Maikel P. Peppelenbosch, Manon C. W. Spaander, Gwenny M. Fuhler. The use of non‐invasive stool tests for verification of Helicobacter pylori eradication and clarithromycin resistance. United European Gastroenterology Journal 2023; 11(9): 894 doi: 10.1002/ueg2.12473
|
| 3 |
Kee Don Choi. Current Trends ofHelicobacter pyloriEradication in Korea. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2015; 15(3): 147 doi: 10.7704/kjhugr.2015.15.3.147
|
| 4 |
Lili Yang, Ao Zou, Huihua Wu, Hai Guo, Fangting Zhang, Bing Zou, Junping Wang, Emily Chia-Yu Su. Application of Visual Gene Clip-Based Tailored Therapy for the Eradication of Helicobacter pylori. BioMed Research International 2021; 2021: 1 doi: 10.1155/2021/6150628
|
| 5 |
P Malfertheiner, F Megraud, C A O'Morain, J P Gisbert, E J Kuipers, A T Axon, F Bazzoli, A Gasbarrini, J Atherton, D Y Graham, R Hunt, P Moayyedi, T Rokkas, M Rugge, M Selgrad, S Suerbaum, K Sugano, E M El-Omar. Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report. Gut 2017; 66(1): 6 doi: 10.1136/gutjnl-2016-312288
|
| 6 |
Haoran Ke, Jing Li, Bingyun Lu, Chenghai Yang, Jiamin Wang, Zhiqing Wang, Le Liu, Ye Chen. The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth‐based quadruple therapy. Helicobacter 2021; 26(1) doi: 10.1111/hel.12768
|
| 7 |
Han Chen, Yini Dang, Xiaoying Zhou, Bingtuan Liu, Shiyu Liu, Guoxin Zhang. Tailored Therapy Versus Empiric Chosen Treatment for Helicobacter pylori Eradication. Medicine 2016; 95(7): e2750 doi: 10.1097/MD.0000000000002750
|
| 8 |
Muhammad Miftahussurur, Yoshio Yamaoka. Appropriate First-Line Regimens to Combat Helicobacter pylori Antibiotic Resistance: An Asian Perspective. Molecules 2015; 20(4): 6068 doi: 10.3390/molecules20046068
|
| 9 |
Azucena Arévalo Galvis, Alba Alicia Trespalacios Rangel, William Otero Regino. Personalized therapy for Helicobacter pylori: CYP2C19 genotype effect on first‐line triple therapy. Helicobacter 2019; 24(3) doi: 10.1111/hel.12574
|
| 10 |
Todor Asenov Angelov, Mila Dimitrova Kovacheva-Slavova, Hristo Ilianov Iliev, Hristo Yankov Valkov, Borislav Georgiev Vladimirov. Gastritis - New Approaches and Treatments. 2019; doi: 10.5772/intechopen.86963
|
| 11 |
Hyungchul Park, Jeong Hoon Lee. Recent Trends in Tailored Treatments for Helicobacter pylori Infection. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2021; 21(2): 115 doi: 10.7704/kjhugr.2021.0005
|
| 12 |
Muhammad Miftahussurur, Yoshio Yamaoka. Diagnostic Methods ofHelicobacter pyloriInfection for Epidemiological Studies: Critical Importance of Indirect Test Validation. BioMed Research International 2016; 2016: 1 doi: 10.1155/2016/4819423
|
| 13 |
Varocha Mahachai, Ratha‐korn Vilaichone, Rapat Pittayanon, Jarin Rojborwonwitaya, Somchai Leelakusolvong, Monthira Maneerattanaporn, Peranart Chotivitayatarakorn, Sombat Treeprasertsuk, Chomsri Kositchaiwat, Pises Pisespongsa, Pisaln Mairiang, Aziz Rani, Alex Leow, Swe Mon Mya, Yi‐Chia Lee, Sengdao Vannarath, Bouachanh Rasachak, Oung Chakravuth, Moe Myint Aung, Tiing‐Leong Ang, Jose D Sollano, Duc Trong Quach, Inchaya Sansak, Olarn Wiwattanachang, Piyathida Harnsomburana, Ari Fahrial Syam, Yoshio Yamaoka, Kwong‐Ming Fock, Khean‐Lee Goh, Kentaro Sugano, David Graham. Helicobacter pylori management in ASEAN: The Bangkok consensus report. Journal of Gastroenterology and Hepatology 2018; 33(1): 37 doi: 10.1111/jgh.13911
|
| 14 |
Chonticha Auesomwang, Monthira Maneerattanaporn, William D Chey, Pattarachai Kiratisin, Somchai Leelakusolwong, Tawesak Tanwandee. Ten‐day high‐dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication. Journal of Gastroenterology and Hepatology 2018; 33(11): 1822 doi: 10.1111/jgh.14292
|
| 15 |
Vladimir I. Simanenkov, Sergei A. Alekseenko. Prospects for personalized Helicobacter pylori eradication therapy. Pro et contra. Terapevticheskii arkhiv 2022; 94(8): 935 doi: 10.26442/00403660.2022.08.201787
|
| 16 |
Xiao-Min Liao, Gao-Hui Nong, Mei-Zu Chen, Xue-Ping Huang, Yun-Yan Cong, Yi-Ying Huang, Bai-He Wu, Jin-Qi Wei. Modified sequential therapy <italic>vs</italic> quadruple therapy as initial therapy in patients with <italic>Helicobacter</italic> infection. World Journal of Gastroenterology 2015; 21(20): 6310-6316 doi: 10.3748/wjg.v21.i20.6310
|
| 17 |
Hitomi Ichikawa, Mitsushige Sugimoto, Ken Sugimoto, Akira Andoh, Takahisa Furuta. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. Journal of Gastroenterology and Hepatology 2016; 31(4): 716 doi: 10.1111/jgh.13233
|
| 18 |
Nazlı Arslan, Özlem Yılmaz, Ebru Demiray-Gürbüz. Importance of antimicrobial susceptibility testing for the management of eradication in <i>Helicobacter pylori</i> infection. World Journal of Gastroenterology 2017; 23(16): 2854-2869 doi: 10.3748/wjg.v23.i16.2854
|
| 19 |
Kyoung Hwa Lee, Soon Young Park, Su Jin Jeong, Da Hyun Jung, Jie-Hyun Kim, Seok Hoon Jeong, Il-Mo Kang, Young Goo Song. Can Aminoglycosides Be Used as a New Treatment forHelicobacter pylori?In vitroActivity of Recently IsolatedHelicobacter pylori. Infection & Chemotherapy 2019; 51(1): 10 doi: 10.3947/ic.2019.51.1.10
|
| 20 |
Ravishankar Ram M., Xinsheng Teh, Tamayanthi Rajakumar, Khean Lee Goh, Alex Hwong Ruey Leow, Bee Hoon Poh, Vanitha Mariappan, Esaki M Shankar, Mun Fai Loke, Jamuna Vadivelu. Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes ofHelicobacter pyloriisolates influence the outcome of triple therapy. Journal of Antimicrobial Chemotherapy 2019; 74(1): 11 doi: 10.1093/jac/dky401
|
| 21 |
S. Yu. Serebrova, E. N. Kareva, D. O. Kurguzova, E. Yu. Demchenkova, N. N. Eremenko, I. A. Mazerkina, L. M. Krasnуkh, G. F. Vasilenko, A. B. Prokofiev. The role of clarithromycin in modern <i>Helicobacter pylori</i> eradication therapy regimens. Meditsinskiy sovet = Medical Council 2023; (8): 68 doi: 10.21518/ms2023-128
|
| 22 |
Larisa H Cavallari, Kristin W Weitzel, Amanda R Elsey, Xinyue Liu, Scott A Mosley, Donald M Smith, Benjamin J Staley, Almut G Winterstein, Carol A Mathews, Francesco Franchi, Fabiana Rollini, Dominick J Angiolillo, Petr Starostik, Michael J Clare-Salzler, David R Nelson, Julie A Johnson. Institutional profile: University of Florida Health Personalized Medicine Program. Pharmacogenomics 2017; 18(5): 421 doi: 10.2217/pgs-2017-0028
|
| 23 |
Tsung‐Jung Lin, Hsi‐Chang Lee, Chih‐Lin Lin, Chung‐Kwe Wang, Kuan‐Yang Chen, Deng‐Chyang Wu. CYP2C19 polymorphism has no influence on rabeprazole‐based sequential therapy. Advances in Digestive Medicine 2017; 4(4): 134 doi: 10.1002/aid2.12134
|
| 24 |
E. V. Luzina, A. A. Dutova, L. B. Lazebnik, N. V. Lareva. Treatment of <i>Helicobacter pylori</i> infection for medical professionals. Experimental and Clinical Gastroenterology 2023; (3): 28 doi: 10.31146/1682-8658-ecg-211-3-28-40
|
| 25 |
M. Teng, A. L. Khoo, Y. J. Zhao, L. Lin, B. P. Lim, T. S. Wu, Y. Y. Dan. Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori
infection. Journal of Clinical Pharmacy and Therapeutics 2015; 40(4): 368 doi: 10.1111/jcpt.12277
|
| 26 |
Luiz Gonzaga Vaz COELHO, James Ramalho MARINHO, Robert GENTA, Laercio Tenório RIBEIRO, Maria do Carmo Friche PASSOS, Schlioma ZATERKA, Paulo Pimentel ASSUMPÇÃO, Alfredo José A BARBOSA, Ricardo BARBUTI, Lucia Libanês BRAGA, Helenice BREYER, Aloisio CARVALHAES, Décio CHINZON, Marcelo CURY, Gerson DOMINGUES, Jorge Luiz JORGE, Ismael MAGUILNIK, Frederico Passos MARINHO, Joaquim Prado de MORAES-FILHO, José Miguel Luz PARENTE, Celso Mirra de PAULA-E-SILVA, José PEDRAZZOLI-JÚNIOR, Ana Flávia Passos RAMOS, Heinrich SEIDLER, José Nonato SPINELLI, José Vitor ZIR. IVTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION. Arquivos de Gastroenterologia 2018; 55(2): 97 doi: 10.1590/s0004-2803.201800000-20
|
| 27 |
Liem T. Nguyen, Vuong B. Nguyen, Tu V. Tran, Loan T. T. Le, Mai H. T. Phuong, Thang Nguyen. Effects of the EM CYP2C19 type and MDR1 3435CC gene on Helicobacter pylori eradication rate in patients with duodenal ulcer by the four-drug regimen of rabeprazole, bismuth, tetracycline, and tinidazole. Pharmacia 2024; 71: 1 doi: 10.3897/pharmacia.71.e108090
|
| 28 |
Tsung-Jung Lin, Hsi-Chang Lee, Chih-Lin Lin, Chung-Kwe Wang, Kuan-Yang Chen, Deng-Chyang Wu. CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for <i>Helicobacter pylori</i> eradication. World Journal of Clinical Cases 2018; 6(12): 514-520 doi: 10.12998/wjcc.v6.i12.514
|
| 29 |
Michael Dore, Blake Cirks, Todd Gleeson. Eradicating Multi-Drug-Resistant Helicobacter pylori with Four Times Daily Lansoprazole. The American Journal of Medicine 2016; 129(4): e21 doi: 10.1016/j.amjmed.2015.11.025
|
| 30 |
Youn I Choi, Jun-Won Chung, Kyoung Oh Kim, Kwang An Kwon, Yoon Jae Kim, Jung Ho Kim, Ja Young Seo, Dong Kyun Park. Tailored eradication strategy <i>vs</i> concomitant therapy for <i>Helicobacter pylori</i> eradication treatment in Korean patients. World Journal of Gastroenterology 2021; 27(31): 5247-5258 doi: 10.3748/wjg.v27.i31.5247
|
| 31 |
S. Yu. Serebrova, D. O. Kurguzova, L. M. Krasnykh, G. F. Vasilenko, E. Yu. Demchenkova, N. N. Eremenko, E. N. Kareva, A. B. Prokofiev. Kinetics of Omeprazole Release from Enteric Dosage Forms of Different Manufacturers. Pharmaceutical Chemistry Journal 2024; 57(10): 1647 doi: 10.1007/s11094-024-03060-x
|
| 32 |
Svetlana Serebrova, Daria Kurguzova, Lyudmila Krasnykh, Galina Vasilenko, Vladimir Drozdov, Natalia Lazareva, Eugenia Shikh, Marina Zhuravleva, Svetlana Rykova, Natalia Eremenko, Elena Kareva, Karin Mirzaev, Dmitriy Sychev, Alexey Prokofiev. Potential factors of Helicobacter pylori resistance to clarithromycin. Drug Metabolism and Personalized Therapy 2022; 37(4): 383 doi: 10.1515/dmpt-2021-0193
|
| 33 |
Kiarash Ghazvini, Hossein Kamali, Seyed-Abolfazl Hosseininasab-nodoushan, Masoud Keikha. The CYP2C19 polymorphisms effects on H. pylori cure rate in proton pump inhibitor-based therapeutic regimens: An updated meta-analysis. Gene Reports 2021; 25: 101340 doi: 10.1016/j.genrep.2021.101340
|
| 34 |
Eunsun Lim, Ik Hyun Jo, Yeon-Ji Kim, Woo Chul Chung. In situ Diagnosis of Helicobacter pylori Infection Using the Endoscopic Kyoto Scoring System. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2021; 21(4): 322 doi: 10.7704/kjhugr.2021.0046
|
| 35 |
Liya Zhou, Jianzhong Zhang, Zhiqiang Song, Lihua He, Yanqing Li, Jiaming Qian, Peng Bai, Yan Xue, Ye Wang, Sanren Lin. Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial. Helicobacter 2016; 21(2): 91 doi: 10.1111/hel.12242
|
| 36 |
Peter Malfertheiner, M. Constanza Camargo, Emad El-Omar, Jyh-Ming Liou, Richard Peek, Christian Schulz, Stella I. Smith, Sebastian Suerbaum. Helicobacter pylori infection. Nature Reviews Disease Primers 2023; 9(1) doi: 10.1038/s41572-023-00431-8
|
| 37 |
Nataliya Pidkovka, Olena Rachkevych, Abbes Belkhiri. Extrahepatic cytochrome P450 epoxygenases: pathophysiology and clinical significance in human gastrointestinal cancers. Oncotarget 2021; 12(4): 379 doi: 10.18632/oncotarget.27893
|
| 38 |
Ali F. Altebainawi, Lulwa A. Alfaraj, Amjad A. Alharbi, Fadwa F. Alkhuraisi, Thamir M. Alshammari. Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database. Therapeutic Advances in Drug Safety 2023; 14: 204209862311540 doi: 10.1177/20420986231154075
|
| 39 |
Colin W. Howden, Kely L. Sheldon, June S. Almenoff, William D. Chey. Pitfalls of Physician-Directed Treatment of Helicobacter pylori: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data. Digestive Diseases and Sciences 2022; 67(9): 4382 doi: 10.1007/s10620-021-07323-5
|